Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 16/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2823876 | 0.98 | MLYCD (0.46) | MLYCDADRB1EPHX2 | |
| Tert-Butyl Formate SCHEMBL27718994 | 0.84 | MLYCD (0.40) | MLYCDEPHX2 | |
| SCHEMBL24968222 | 0.80 | TDP1 (0.55) | MLYCD | |
| SCHEMBL14083420 | 0.78 | MLYCD (0.48) | MLYCD | |
| SCHEMBL28911177 | 0.76 | MLYCD (0.49) | MLYCD | |
| Hydrochloric Acid SCHEMBL2824877 | 0.76 | MEN1 (0.39) | MLYCDADRB1EPHX2 | |
| SCHEMBL2628928 | 0.75 | CHRNB2 (0.47) | — | |
| SCHEMBL23296741 | 0.75 | MLYCD (0.48) | MLYCD | |
| Hydrochloric Acid SCHEMBL23296989 | 0.74 | MLYCD (0.47) | MLYCD | |
| SCHEMBL25072383 | 0.74 | HDAC3 (0.59) | MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102797043-B | Medicinal molecular fragment library and construction process thereof | Tianli (Tianjin) Technology Co., Ltd. (CN) | 2015-11-25 | — | — | CN | claimed |
| CN-102797043-A | Medicinal molecular fragment library and construction method thereof | CBB NETWORK CO LTD | 2012-11-28 | — | — | CN | claimed |
| EP-4234551-A2 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2023-06-22 | — | — | US | disclosed |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2023-06-22 | — | — | US | disclosed |
| US-11566020-B1 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| WO-2023001247-A1 | PYRIDAZINONE COMPOUND | 南京明德新药研发有限公司 | 2023-01-26 | — | — | WO | disclosed |
| US-11014913-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| CN-105712952-B | 2-substituted oxy-5-methylsulfonyl phenyl piperazine amide analogue and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2021-03-26 | — | — | CN | disclosed |
| US-20210024502-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2021-01-28 | — | — | US | disclosed |
| US-10870641-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| WO-2020244460-A1 | HETEROAROMATIC ACETAMIDE DERIVATIVE, AND PREPARATION AND USE THEREOF | 杭州维坦医药科技有限公司 | 2020-12-10 | — | — | WO | disclosed |
| US-20200123134-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2020-04-23 | — | — | US | disclosed |
| US-10550105-B2 | Pyridazinones as PARP7 inhibitors | Ribon Therapeutics Inc. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190330194-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2019-10-31 | — | — | US | disclosed |
| CN-102797043-B | Medicinal molecular fragment library and construction process thereof | Tianli (Tianjin) Technology Co., Ltd. (CN) | 2015-11-25 | — | — | CN | disclosed |
| CN-101885708-B | 5-polyfluoroalkyl group substituted 2-aminothiazole compound, synthesis method and application thereof | SHANGHAI INST ORGANIC CHEM | 2013-03-06 | — | — | CN | disclosed |
| CN-102797043-A | Medicinal molecular fragment library and construction method thereof | CBB NETWORK CO LTD | 2012-11-28 | — | — | CN | disclosed |
| CN-101885708-A | 5-polyfluoroalkyl group substituted 2-aminothiazole compound, synthesis method and application thereof | SHANGHAI INST ORGANIC CHEM | 2010-11-17 | — | — | CN | disclosed |
| EP-1838308-B1 | [4-(HETEROARYL)PIPERAZIN-1-YL]-(2,5-SUBSTITUTED -PHENYL)METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024502-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | MLYCD 2813/4885ADRB1 3022/4885EPHX2 3652/4885 |
| US-10550105-B2 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | MLYCD 2813/4885ADRB1 3022/4885EPHX2 3652/4885 |
| US-20190330194-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | MLYCD 2813/4885ADRB1 3022/4885EPHX2 3652/4885 |
| US-11014913-B2 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | MLYCD 2813/4885ADRB1 3022/4885EPHX2 3652/4885 |
| US-11566020-B1 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | MLYCD 2813/4885ADRB1 3022/4885EPHX2 3652/4885 |
| US-10870641-B2 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | MLYCD 2813/4885ADRB1 3022/4885EPHX2 3652/4885 |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | MLYCD 2813/4885ADRB1 3022/4885EPHX2 3652/4885 |
| US-20200123134-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | MLYCD 2813/4885ADRB1 3022/4885EPHX2 3652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.